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BACKGROUND: Genome-wide association studies (GWASs) have enriched the fields of genomics and drug development.
Adrenocortical carcinoma (ACC) is a rare cancer with a bimodal age distribution and inadequate treatment options. Paediatric ACC
is frequently associated with TP53 mutations, with particularly high incidence in Southern Brazil due to the TP53 p.R337H (R337H)
germline mutation. The heterogeneous risk among carriers suggests other genetic modifiers could exist.
METHODS: We analysed clinical, genotype and gene expression data derived from paediatric ACC, R337H carriers, and adult ACC
patients. We restricted our analyses to single nucleotide polymorphisms (SNPs) previously identified in GWASs to associate with
disease or human traits.
RESULTS: A SNP, rs971074, in the alcohol dehydrogenase 7 gene significantly and reproducibly associated with allelic differences in
ACC age-of-onset in both cohorts. Patients homozygous for the minor allele were diagnosed up to 16 years earlier. This SNP resides
in a gene involved in the retinoic acid (RA) pathway and patients with differing levels of RA pathway gene expression in their
tumours associate with differential ACC progression.
CONCLUSIONS: These results identify a novel genetic component to ACC development that resides in the retinoic acid pathway,
thereby informing strategies to develop management, preventive and therapeutic treatments for ACC.
British Journal of Cancer (2020) 122:1231–1241; https://doi.org/10.1038/s41416-020-0764-3
BACKGROUND
Adrenocortical carcinoma (ACC) is a rare cancer that usually occurs
in the first or after the fifth decade of life.1 The incidence of most
paediatric carcinomas increases progressively with age, but ACC
has a peak incidence between birth and 4 years of age.2 Li-
Fraumeni syndrome (LFS) families have a higher risk of developing
paediatric ACC, with more than 50% of all children with ACC
having a heritable TP53 mutation.1 The germline R337H mutation
was spread through a founder effect.3,4 Newborn screening for the
R337H in Southern and South-eastern Brazil showed that this
mutation has a frequency of 0.21–0.30%.5–7 This mutation is
responsible for the increased incidence of paediatric ACC in
Paraná state (3.4 per million before the age 15 years per year
compared to 0.3 per million in the USA, or 6.4/million children
younger than 10 years per year).2,5 A hospital-based cohort
estimated that the penetrance of this mutation for paediatric ACC
is 10%.8 However in a large population-based cohort, the
penetrance for paediatric ACC is less than 5%, whilst the overall
cancer risk among females and males is less than 50% before the
seventh decade.5,7 The frequency of R337H prevalence among
paediatric ACC varies from 75–96%, and is nearly 15% among
adult ACC in Southern and South-eastern Brazil.7,9,10 The
phenotypic heterogeneity among R337H carriers in terms of
cancer risk and the variability in age-of-onset may indicate the
involvement of environmental and/or genetic variants that are
able to modulate cancer development.5,7 The enormous hetero-
geneity in cancer development noted in families carrying the
germline R337H mutation5 has prompted us to gain further insight
into potential genetic factors cooperating to modify the age-
dependent incidence of cancer onset in the adrenal cortex.
ACC requires more effective treatment strategies. The prognosis
of children with residual or metastatic ACC is dismal11 and can be
worse in older children12 and adult patients.13,14 Knowing which
gene(s) play important roles in the multistep tumorigenesis
process in adrenocortical cells will certainly inform strategies to
develop preventive and/or therapeutic protocols. Growing
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genomic data has allowed recent studies to highlight the
importance of heritable genetic determinants in identifying
potential drug targets and disease treatments.15–17 For example,
one analysis showed that if a drug target has heritable genetic
data supporting its role in a given disease, the chance of
successful clinical development of a drug is doubled.16 Through
advances in genome genotyping and sequencing technologies,
the identification of genetic variations associating with disease
traits has rapidly increased. For example, GWASs have identified
over 900 SNPs significantly associated with cancer susceptibility
traits.18 However, the necessity of large cohort sizes in GWASs to
overcome the burden of multiple hypothesis testing has resulted
in a relative deficit in our knowledge of the genetic variants
underlying rare cancers like ACC.19,20
The genetic data supporting the role of p53 in ACC has
improved the early diagnosis of ACC in TP53 mutation carriers
through asymptomatic screening.5,21 However, targeting p53 in
either the preventative or therapeutic setting remains a
challenge.1 The identification of other more druggable gene
targets with genetic associations with ACC could prove useful,
whereby SNPs in genes that associate with differential ACC cancer
risk in TP53 mutation carriers could help to identify novel
druggable genes and/or pathways. SNPs in the p53 pathway
have been clearly shown to associate with differential cancer risk.
Indeed, SNPs in well-described p53 pathway genes have been
frequently identified in GWASs of seemingly sporadic cancers.18 In
fact, one p53 pathway SNP, MDM2 SNP309 that associates with
differential expression levels of a key regulator of p53, has been
shown to modify cancer risk in TP53 mutation carriers with LFS.22
Specifically, LFS families with more penetrant TP53 mutations
relative to the Brazilian R337H, are at higher risks of developing
many types of cancer, such as sarcomas, breast, and brain cancers,
as well as ACC. MDM2 SNP309 has been shown to modify this
cancer risk in multiple cohorts of TP53 mutation carriers in an age-
and gender-dependent manner.22–26 Importantly, genetically
engineered mouse models carrying either alleles of MDM2
SNP309 and a highly penetrant LFS p53 mutation demonstrated
similar allele-specific differences in age-dependent cancer inci-
dence.26 Together, observations such as these suggest that SNPs
could potentially modify ACC cancer risk. Here, we studied two
independent cohorts of ACC patients (paediatric and adult) to
demonstrate that a SNP in a druggable gene and pathway
significantly associates with ACC age-dependent incidence.
METHODS
Study cohorts
TP53 p.R337H paediatric ACC cohorts. A cohort of children
diagnosed with ACC with the R337H germline mutation was used
in this study. We divided this cohort into a discovery cohort (BRZ1,
N= 26) and a validation cohort (BRZ2, N= 16) based on when the
DNAs were received from the Pathology unit. The patients were
treated in the Pequeno Príncipe Hospital, Brazil. This study was
approved by the Ethics Committee from Pequeno Príncipe
Hospital, and authorisation was obtained by signing a consent
form. Clinical data that included the age at diagnosis for each
patient, gender, and TP53 mutation status were available.
Adult ACC cohort. A retrospective database for primarily sporadic
ACC patients (N= 92) was analysed from the Cancer Genome
Atlas.27 These patients were diagnosed with adult ACC and blood-
derived genotype data from the Affymetrix™ Genome-Wide
Human SNP Array 6.0 was available together with the relevant
clinical information. Approval from the National Institute of Health
(NIH) Data Access Committee was obtained (request number
34594–5). Somatic mutations of TP53 for this data set were
retrieved from cBioPortal (http://www.cbioportal.org/) website
(accessed December 2018).
Genomic DNA preparation
Genomic DNAs from the BRZ patients were extracted from
peripheral blood using the ReliaPrep™ gDNA kit as per the
manufacturer’s recommendations (A2051, Promega).
SNP genotyping
Genomic DNAs from the BRZ cohort were genotyped using the
Infinium© LCG assay on the Human Omni 2.5–8 v1.3 BeadChip
(Illumina platform), according to the manufacturer’s instructions
and at the High-Throughput Genomics at the Wellcome Trust
Centre for Human Genetics, University of Oxford.
Cancer GWAS and GWAS SNPs
The GWAS Catalog was downloaded from the European Bioinfor-
matics Institute (EMBL-EBI) website (https://www.ebi.ac.uk/gwas/)
on February 2018. We found 35,705 GWAS lead SNPs in studies
with individuals with European (EUR) ancestry. We then retrieved
all closely linked SNPs (proxies) based on the 1000 Genomes
phase 3 data acquired through the web server: rAggr (http://raggr.
usc.edu), and only considered the proxies that meet the following
criteria: population: EUR; minimum MAF (minor allele frequency):
≥0.01; r2 ≥ 0.8; maximum distance: 500 kb; maximum # Mendel
error: 1; Hardy-Weinberg equilibrium (HWE) p-value: 1e-6; and
minimum genotyping rate of 95%. Cancer GWAS proxy SNPs and
GWAS proxy SNPs were then pulled to intersect with the
significant SNPs genotyped on the Infinium array as
described below.
SNPs on the Infinium genotyping array with MAF ≥ 0.05 were
selected based on dbSNP150 hg19 genome build. Briefly,
snp150Common.txt were accessed in August 2018 from http://
hgdownload.soe.ucsc.edu/goldenPath/hg19/database/. Triallelic
SNPs were removed. SNPs with MAF ≥ 0.05 (8,209,080 SNPs) were
then pulled to identify the number of SNPs genotyped on the
Infinium array with MAF ≥ 0.05 among cancer GWAS and GWAS
SNP lists.
SNP analyses
The following methods were used to analyse the BRZ cohort. First,
SNPs mapped to chromosome: 0 (unknown), XY (pseudoautoso-
mal), Y, or MT (mitochondria) and SNPs mapped to chromosome
position 0 were removed. Only females were considered for the
SNPs on the X Chromosome. A MAF threshold was set at 0.05
(SNPs with MAF < 0.05 were removed). Nonpolymorphic SNPs and
duplicated SNPs (SNPs with two rsIDs at the same position) and
SNPs that failed genotyping for all patients were removed. For
each SNP, heterozygous and homozygous minor allele genotype
calls were combined into the same group for statistical analysis, to
overcome the missing genotypes and/or low patient numbers per
genotype within these two small cohort sizes. A Log-ranked non-
parametric test, the Mann–Whitney U test, two-sided, was used to
determine statistical differences between genotype and age-of-
tumour onset. The analysis was performed in base R using the
Wilcoxon test. SNPs in the BRZ1 cohort with a raw p-value < 0.05 in
the Mann–Whitney U test were then likewise tested for
significance in the BRZ2 cohort and examined for consistent
effects. The subset of SNPs having a raw p-value < 0.05 in the
Mann–Whitney U test in both cohorts and showing a consistent
effect were considered for further examination and validation in
the adult ACC cohort.
For the primarily adult ACC cohort, reference SNPs rsIDs were
extracted from the Affymetrix Genome-Wide Human SNP 6.0 Array
names according to https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=%20GPL6801 (accessed July 2018). The primarily adult
ACC cohort genotyping was on the Affymetrix SNP array, while the
paediatric BRZ cohorts were genotyped using the Infinium LCG
array. Thus, when testing significant SNPs (raw p < 0.05) identified
in both BRZ cohorts, we either utilised the genotypes for the same
SNP, if directly genotyped SNP on the Affymetrix SNP array, or we
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utilised the genotypes of a closely linked proxy SNP genotyped on
the Affymetrix SNP array. Proxy SNPs were determined using
rAggr (http://raggr.usc.edu) for the EUR population. If multiple
proxies for a given significant SNP were genotyped in the adult
ACC cohort, the most closely linked SNP was utilised. The
heterozygous and homozygous minor allele genotypes were
combined for statistical analyses if the number of minor
homozygotes were ≤4. A Log-ranked non-parametric test, two-
sided, the Mann–Whitney U test (2 groups) or the Kruskal–Wallis
test (three groups), was applied to determine statistical differences
between genotype and age of tumour onset. P-values were
subsequently adjusted for multiple hypothesis correction (Bonfer-
roni correction).
mRNA expression levels and survival analyses
RNA-seq data for the adult ACC cohort (illumine hiseq Level 3
RSEM normalised genes) were retrieved from http://firebrowse.
org/?cohort=ACC accessed February 2019. Genes involved
in the regulation of retinoid metabolism and those
involved in retinoic acid receptor-mediated signalling
were retrieved from http://software.broadinstitute.org/gsea/
msigdb/cards/GO_RETINOIC_ACID_METABOLIC_PROCESS.html
(GO:0042573) and http://software.broadinstitute.org/gsea/
msigdb/cards/PID_RETINOIC_ACID_PATHWAY.html, accessed
18 July 2019. The cut-off point between high and low mRNA
expression levels for each gene was computed based on the
maximally selected rank statistics using the “survminer”
package in R. mRNA levels with values above the cut-off point
were considered high and below were considered low.
Survival data for the adult ACC were retrieved from Liu et al.,28
Table S1 Tab TCGA-CDR, accessed May 2019. The progression-free
interval (PFI) endpoint was analysed (PFI, the length of time during
and after the treatment of a disease when a patient lives with the
disease but it does not get worse). The patients in the adult ACC
cohort were randomly separated into Discovery and Validation
cohort pairs at 50:50 ratios 10 times using the “R Base” package.29
We first performed Kaplan–Meier survival analyses to estimate the
survival probability as a function of time in relation to mRNA
expression levels for each transcript (patients with low versus high
expression levels in tumours). The Log-Mantel and Haenszel
survival test (a Log-rank test) was used to determine the statistical
differences betwen the groups. Genes that were significant with
p < 0.05 were tested in the paired Validation cohort. In the
Validation cohort the analyses were undertaken in the exact same
manner except for the final adjustment of the p-values for
multiple hypothesis testing, which was performed using the
Bonferroni method. Adjusted p < 0.05 were considered significant.
These analyses were performed in each of the 10 Discovery/
Validation pairs and those genes whose transcript levels
associated with PFI six times or more were considered hits.
Gene expression data from two independent paediatric ACC
cohorts were used in this study: the Children’s Oncology Group
(COG, n= 34, accession number; GSE76019) and International
Pediatric Adrenocortical Tumor Registry group (IPACTR, n= 19,
accession number; GSE76021). The data from the COG and the
IPACTR were accessed via the Gene Expression Omnibus (GEO) in
June 2019. For these cohorts, the progression-free survival (PFS)
endpoint was considered (PFS, the time elapsed between protocol
enrolment and the date of disease progression, death, or most
recent follow-up).30 mRNA expression data was available as a
normalised log2 signal. The data were generated on two different
array platforms: IPACTR on the GLP96 platform, COG on the
GPL13158 platform. In order to maximise consistency in the
analyses, we considered only probes with the same Transcript ID
design. The cut-off point between high and low mRNA expression
levels, the statistical difference in survival, and the approach used
to validate the significant genes were performed as
described above.
All analyses were performed on R (version 3.5.1) using the
following packages “data.table”, “dplyr”, “reshape2”, “tidyr”, “plyr”,
“survminer” and “survival” in addition to base R. Plots were
generated using Prism 7 (GraphPad) and R using the “qqman”,
“gplots” and “ggplot2” packages. All statistical tests were two-
sided except where otherwise stated. Pathway diagram was
created with BioRender.com.
RESULTS
In order to identify potential genetic modifiers underlying ACC
development that could improve cancer risk management and
treatment, we genotyped a total of 42 TP53 R337H carriers with
ACC, divided into a discovery cohort (BRZ1, N= 26) and a
validation cohort (BRZ2, N= 16). All BRZ samples had a >98%
genotype call rate, with an average overall call rate of 99.6%. The
clinical characteristics of the paediatric patients of both cohorts
are shown in Supplementary Table 1. All children (29 girls and 13
boys) were carriers of the R337H mutation and were diagnosed at
ages ranging from 0.14 to 14.7 years. Family history showed that
three children were from LFS families, 17 children were from Li-
Fraumeni-Like (LFL) families and 22 with no LFS/LFL family
histories (Supplementary Table 1) according to the most stringent
criteria.31
Cancer GWAS SNPs and ACC age-of-onset in R337H mutation
carries
The small cohort size and narrow age-of-onset window necessi-
tated a focused analytical approach in the search for SNP
modifiers. Therefore, we focused our search on SNPs that have
been previously found to associate with differential cancer risk in
GWAS (Fig. 1a). This process began by procuring the 2,668 GWAS
lead SNPs in the GWAS catalog found to significantly associate
with cancer risk among Europeans. In total, these SNPs were found
to associate with differential risk of 33 different cancers. Next,
proxy SNPs linked to these cancer GWAS tags were obtained. SNP
linkage information is not available for the Brazilian population,
but it is thought that the R337H mutation originates from a
founder effect of European origin.3,4 Therefore, we retrieved
proxies that are linked in the EUR. This resulted in 55,294 cancer
GWAS SNPs. Of the cancer GWAS SNPs, 6,729 SNPs were on the
Infinium genotyping array with MAF ≥ 0.05. 303 cancer GWAS
SNPs showed significant allelic differences with ACC age-of-onset
in BRZ1 (p < 0.05, Mann–Whitney U test). 282 SNPs were tested in
BRZ2 (MAF ≥ 0.05 in BRZ2), of these, seven SNPs were also
associated significantly (p < 0.05, Mann–Whitney U test) with
differential age-of-onset in a consistent manner whereby the same
allele associated with an earlier diagnosis (Fig. 1a).
Cancer GWAS SNPs and ACC age-of-onset in sporadic adult ACC
The cohort of primarily adult ACC patients included 92 individuals
(60 women and 32 men) diagnosed with a mean age of 47.16
years (range 14–83 years). Two patients were carriers of the R337H
germline mutation (diagnosed at ages 23 and 30 years). For all
patients, genotyping information was available from blood DNA
(Affymetrix SNP 6.0 Array), while somatic mutation data from the
tumours was available for 91 patients (Supplementary Table 2).
Out of the seven SNPs that significantly associated with
differential age-of-onset of paediatric ACC, six SNPs could be
studied in the primarily adult ACC cohort, as three were
successfully genotyped with the Affymetrix array, and three SNPs
had successfully genotyped proxies. One of these six SNPs,
rs971074, significantly associated with differential age-of-onset
(adj. p= 0.00114, Kruskal–Wallis test). rs971074 (C/T,
chr4:100341861, Genome Reference Consortium Human Build 37
(GRCh37)/hg19) is a synonymous SNP located in exon 6 of the
alcohol dehydrogenase 7 gene (ADH7) gene (Fig. 1b-d). The TP53
mutation carriers with rs971074 minor allele (CT) were diagnosed
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at a median age of 0.85 year in the BRZ1 and at a median of 0.585
year in BRZ2 cohort. However, carriers of the homozygous major
allele (CC) were diagnosed at a median age of 2 years (BRZ1, p=
0.0153, Mann–Whitney U test), and at a median of 2.25 years
(BRZ2, p= 0.0197, Mann–Whitney U test) Table 1, Fig. 2a, b. When
the patients of BRZ1 and BRZ2 are combined (BRZ), CT patients
were diagnosed at a median age of 0.67 years compared to a
median age of 2.17 years for CC patients (p= 0.00068,
Mann–Whitney U test) Table 1 and Fig. 2c.
In the primarily adult ACC cohort, CC patients were diagnosed
16 years earlier than TT patients (at a median age of 45 and 29
years, respectively. p= 0.0498, Mann–Whitney U test) Table 2 and
Fig. 2d, in a manner similar to the paediatric cohort. In contrast to
the paediatric cohort, patients heterozygous for rs971074 were
diagnosed at older ages (16 years later than CC patients, p=
0.00038; 32 years later than TT patients, p= 0.00414,
Mann–Whitney U test).
Altogether, these data show that the rs971074 SNP associates
with differential ACC age-of-onset in both TP53 mutation carriers
and non-carriers alike. However, in ACC patients with no inherited
TP53 mutations, the TP53 gene is known to be somatically
mutated (19.6%, cBioPortal). In the adult cohort, 18 patients
(19.6%) had known pathogenic TP53 mutations in their tumours,
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Fig. 1 Cancer GWAS approach to identify the genetic modifiers in ACC age-of-onset. a A flow chart representing the focused analytical
approach taken to identify potential cancer GWAS SNPs which associate with differential age of ACC onset. b–d Manhattan plot representing
cancer GWAS SNPs tested in BRZ1 (discovery) cohort with p-value represented in −log10(p) for each SNP (n= 6059) (b). Manhattan plot
representing the significant cancer GWAS SNPs (p < 0.05) in BRZ1 and their validation in the BRZ2 cohort (n= 282, out of 303 significant in
BRZ1) (c). Manhattan plot representing significant the cancer GWAS SNPs in both BRZ1 and BRZ2 and validated in the adult ACC cohort (n= 6,
out of 7 significant in BRZ1 and BRZ2) (d). The significant SNP in the 3 cohorts is marked in red and pointed with an arrow.
Table 1. rs971074 in the paediatric BRZ ACC cohort.
Cohort Patient
numbers
Mean
(years)
Median
(years)
BRZ1 Genotype Major (CC) 21 2.9 2
Minor (CT) 5 1.168 0.83
MAF 0.0962
p-value (MWU) 0.0153
BRZ2 Genotype Major (CC) 12 4.13 2.25
Minor (CT) 4 0.765 0.585
MAF 0.125
p-value (MWU) 0.0197
BRZ Genotype Major (CC) 33 3.345 2.17
Minor (CT) 9 0.999 0.67
MAF 0.1071
p-value (MWU) 0.000068
MAF minor allele frequency, MWU Mann–Whitney U test.
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and 2 had the R337H germline mutation. When we restrict our
analyses to those 71 patients without either inherited or somatic
TP53 mutations, and excluding the patient with no somatic
mutation data, similar allelic differences in the age-of-onset were
found (p= 0.00075, Kruskal–Wallis test, Table 2 and Supplemen-
tary Fig. 1), wherein TT patients were diagnosed at a median
age of 26 years compared to a median age of 46.5 years for the
CC patients. This corresponds to a 20.5 year earlier diagnosis for
TT patients demonstrating the apparent TP53 mutation-
independence of these associations.
It is important to note that in a smaller paediatric ACC cohort
(N= 21, The Hospital for Sick Children, Canada) of TP53 mutation
carriers with more penetrant mutations and diagnosed at ages
ranging from 1 to 17.83 years (Supplementary Table 3), no
significant difference in ACC age-of-onset with the rs971074 SNP
genotype was observed (Supplementary Table 4).
GWAS SNPs and ACC age-of-onset
The rs971074 SNP was included in our list of cancer GWAS SNPs
due to its association with differential cancer risk in the upper
aerodigestive tract, particularly oesophageal cancers.32,33 To
further explore this association in ACC, we included GWAS SNPs
known to associate not only with cancer, but also with all other
diseases and traits that have been studied in GWAS. Specifically, in
total, 31,392 lead SNPs can be found in the GWAS catalog. For
these, we identified 526,636 closely linked proxy SNPs. Of these,
67,996 SNPs with MAF ≥ 0.05 were present on the genotyping
array. Among these, 2,878 SNPs were associated with the ACC age-
of-onset in BRZ1 (p < 0.05, Mann–Whitney U test). 2,644 SNPs were
tested in BRZ2 (MAF ≥ 0.05), of these, 34 SNPs were also found to
be associated with age-of-onset in a consistent manner (p < 0.05,
Mann–Whitney U test). In the adult ACC cohort, we were able to
explore potential associations with differential age-of-onset for 23
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Fig. 2 rs971074 SNP modifies the age of ACC onset. Kaplan–Meier plots representing the age of tumour onset for both the major allele
homozygous (CC) and the minor allele heterozygous (TC) and homozygous (TT). In a the ages of onset of the first paediatric ACC cohort is
plotted (BRZ1) (p= 0.0152, two-sided Mann–Whitney U test). In b the second paediatric cohort is plotted (BRZ2) (p= 0.0197, two-sided
Mann–Whitney U test). In c the paediatric cohort combined (BRZ) is plotted (p= 0.00063, two-sided Mann–Whitney U test). In d the patients in
the primarily adult ACC cohort are plotted (n= 92), p= 0.00019, Kruskal–Wallis test.
Table 2. rs971074 in the adult ACC cohort.
Cohort Patient number Mean
(years)
Median
(years)
Adult ACC Genotype CCa 68 45.01 45
CTb 18 60.1 61
TTc 6 32.67 29
MAF 0.163
p-value (KW) 0.00019
adjusted
p-value
(Bonferroni)
0.00114
p-value (MWU)
(CC vs TT)
0.0498
p-value (MWU)
(CC vs CT)
0.00038
p-value (MWU)
(TT vs CT)
0.0041
Adult ACC
(somatic wild
type p53)
Genotype CC 50 45.34 46.5
CT 16 60.19 61
TT 5 32 26
MAF 0.1831
p-value (KW) 0.00075
MAF minor allele frequency, KW Kruskal–Wallis, MWU Mann–Whitney U test.
aCC: Homozygous major.
bCT: Heterozygous.
cHomozygous minor.
A common polymorphism in the retinoic acid pathway modifies. . .
M Surakhy et al.
1235
of the 34 SNPs (8 SNPs directly and 15 SNPs through proxies)
Fig. 3a–d. Interestingly, only the rs971074 SNP was significant after
multiple hypothesis correction (adj. p= 0.0044, Kruskal–Wallis
test), thereby underlining the importance of the GWAS SNP’s
association with cancer and not other diseases and traits.
Expression levels of RA pathway genes in ACC associate with
tumour progression
ADH7 is involved in the production of RA from retinol (also known
as vitamin A), which can induce differentiation and inhibit cellular
growth (Fig. 4a). This pathway is therapeutically malleable and RA
isomers are utilised in both cancer prevention and treatment
strategies.34,35 Our data thus far suggest that the RA pathway
could be important in ACC. To further test this hypothesis, we
explored the association of RA pathway gene expression with ACC
progression and survival. We focused our analyses on 50 RA
pathway genes, whereby 30 genes are known to be involved in RA
signalling and 20 genes in RA metabolism. In the adult ACC
cohort, we processed RNA-seq data derived from tumours. We
were able to detect significant RNA levels of 48 of the 50 genes.
Next, we randomly assigned the patients into Discovery and
Validation groups at a 50:50 ratio. We repeated these analyses ten
times. For each Discovery group, we first separated the patients
into two groups based on the expression levels of a given RA
pathway gene using a Rank statistic (high and low expressing
groups). We then explored potential differences in PFI between
these two groups using a Log-rank test. In the patients of the
Discovery cohorts, we identified an average of 28 transcripts
(ranging from 20 to 33) that were associated with PFI with a raw
p < 0.05. Next, we sought validation of the associations identified
in the Discovery groups, in the paired Validation groups. In the
Validation groups, the raw-p-values for each association were
adjusted for multiple hypothesis testing and significance was
considered with an adjusted p < 0.05 (Bonferroni adjustment,
Supplementary Table 5). Interestingly, expression levels of 5
different genes consistently associated with PFI in minimally 6
different Discovery/Validation cohort pairs (Fig. 4b). One of the
genes (BCO2) is involved in RA metabolism, while the other 4
genes (RARB, SCPEP1, CDK1 and PRKCA) are involved in RA
signalling (Fig. 4c).
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These data implicate a role for RA pathway genes in ACC
progression. To further test this hypothesis, we next explored
similar associations in paediatric ACC. We utilised two indepen-
dent paediatric ACC cohorts with microarray gene expression data
associated with outcome information (IPACTR and COG).30 We
investigated the expression data from histologically confirmed
ACC paediatric patients (19 from the IPACTR and 34 from the
COG).30 We analysed these cohorts in a similar manner as with the
adult ACC cohort, and thus randomly assigned the IPACTR as the
Discovery cohort and the COG as the Validation cohort, and
explored potential associations of gene expression for the 50 RA
pathway genes with PFS using a Log-rank test. Specifically, as the
cohorts utilised different arrays, we restricted our analyses to
shared probes to maximise our ability to draw comparisons. Out of
the 50 RA pathway genes, we were able to identify 79 shared
probes for 43 RA pathway genes. Using these data and the above-
described analytical pipeline, we determined that the expression
levels of 4 different transcripts from three different genes
associated with PFS in both cohorts: Discovery cohort: raw p <
0.05; Validation cohort: adjusted p < 0.05. One of the genes
(ALDH1A2) is involved in RA metabolism, while the other two
genes (CDK1, and PRKCA) are involved in RA signalling (p < 0.05,
Bonferroni adjustment, Fig. 5a–c, Supplementary Table 6).
DISCUSSION
In this report, we explored whether SNPs could potentially modify
ACC cancer risk and thus give us a better understanding of ACC
development and possible indications of novel treatments. Due to
the fact that this is a rare cancer, we undertook a focused
analytical approach, whereby we restricted our analyses to SNPs
previously identified in GWAS studies to associate with disease or
other human traits. We utilised two independent cohorts of ACC
patients and clearly demonstrated that a SNP (rs971074 in ADH7)
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in a druggable pathway significantly associated with the age of
ACC onset, suggesting an increased risk associated with ACC age-
of-onset. We demonstrated that the minor allele of rs971074 in
ADH7 associates with a significantly earlier age of paediatric ACC
in R337H carriers (CT) and adult ACC (TT), relative to patients
homozygous for the major allele (CC) in a manner that is
seemingly independent of both inherited and somatic TP53
mutations. It is important to note that although the associations
with the age-of-onset for the different genotypes were significant
in both the paediatric and adult ACC cohorts, there are some
differences. For example, in the adult cohort, the heterozygous
patients (CT) demonstrated the latest average age-of-onset, while
in the paediatric, the heterozygotes were the youngest. It will be
important to validate the associations in a second adult cohort,
but this could further reflect the known genetic differences in the
development of paediatric and adult ACC.36,37 For instance,
amplification of chromosome 9q occurs in 90% of paediatric
ACC tumours but not in adult tumours.36 Moreover, although
upregulation of the Wnt/β-catenin signalling is common in
paediatric and adult ACC, mutations in ZNRF3 are only observed
in adult tumours.36,37
We went on to demonstrate that amongst all SNPs identified to
associate with human diseases or traits, only this SNP significantly
and reproducibly associated with ACC age-of-onset. Intriguingly,
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this SNP was shown to associate in GWAS with differential risk for
the development of cancer, namely with upper aerodigestive tract
cancer risk.32,33 The rs971074 SNP is a synonymous SNP found in
exon 6 of ADH7. ADH7 is important in retinoic acid (RA) signalling
as it is crucial for the production of RA from retinol (also known as
vitamin A).38 RA and its isomers such as all-trans-RA (ATRA), 9-cis
RA, and 11-cis RA39 are involved in the regulation of different
genes that are important for cell growth, differentiation, and
apoptosis by activating the nuclear retinoid receptors, RA
receptors (RARs) and retinoid X receptors (RXRs).40 The importance
of ADH7 and RA in the adrenal gland has also been clearly shown
in mammals. In mice, class IV ADH (Adh4, recently re-named Adh7,
http://www.informatics.jax.org/searchtool/Search.do?
query=adh&submit=Quick%0D%0ASearch) and RA are expressed
in the embryonic adrenal glands and adult adrenal cortex.41,42 In
fact, class IV ADH null mice are normal and fertile, with no growth
defects when maintained on a normal diet. However, they show
100% lethality when placed on a vitamin A-deficient diet.38,43
These data suggest that ADH7 is important in producing RA during
development when vitamin A levels are low. Moreover, RA
signalling may be involved in the regulation of immune cells.
For example, reduction of primary murine B cell adhesion was
observed after removing retinoids or by treatment with corticos-
teroids.44 These effects could suggest a putative RA-mediated
activation of the immune system against ACC, a role that could be
more important in paediatric and adult patients with and without
Cushing syndrome.45
Although the effects of this SNP on RA signalling and ACC
development remain to be further explored in mechanistic
studies, we have been able to provide further evidence for the
importance of the RA pathway genes in ACC. Specifically, using a
two-step validation strategy to identify transcripts that signifi-
cantly and reproducibly associate with ACC progression, we clearly
demonstrated that transcripts for multiple RA pathway genes
associate with differential progression in both adult (five genes)
and paediatric (three genes) ACC. In both groups, we identified
genes clearly involved in RA metabolism in a manner that could
suggest that lower RA production associates with faster ACC
progression. Specifically, in the adult ACC cohort, patients with
low levels of beta-carotene oxygenase 2 (BCO2) transcript
associated with shorter PFI. BCO2 is a mitochondrial enzyme
involved in the production of retinoids from provitamin A
carotenoids, which is a key source of retinoids in our diet.46
Specifically, BCO2 asymmetrically cleaves β-carotene to generate
β-apo-10′-carotenal, which is then converted to retinoids by
BCO1.47,48 In the paediatric ACC cohorts, shorter PFS was seen in
patients with low transcript levels of Aldehyde Dehydrogenase 1
Family Member A2 (ALDH1A2). ALDH1A2 is an enzyme involved in
the rate-limiting step of RA production from retinaldehyde.49,50
Consistent with the hypothesis that less RA signalling results in
faster ACC progression is the association of low mRNA levels for
the RA receptor beta (RARB) with faster progression of adult ACC
patients. RARB is a member of the RAR family that binds the
retinoid ATRA to further activate down-stream RA signalling.51
This is not the first time that lower expression levels of the RA
pathway genes have been implicated in ACC.52 In a meta-analysis
of gene expression data from 164 adult adrenal tumours (97
adenomas and 67 carcinomas), significant reductions of three RA
pathway transcripts were noted in malignant ACC relative to
benign adrenal tumours. Specifically, ALDH1A1, ALDH1A3, and RXRA
mRNAs were much lower in ACCs relative to adrenocortical
adenoma.52 The authors, therefore, hypothesised that RA produc-
tion and signalling might be reduced in ACC and, therefore, its re-
activation could be a therapeutic option,52 as retinoids are already
used in cancer treatment for acute promyelocytic leukaemia, and in
cancer prevention for precancerous lesions in leukoplakia, actinic
keratosis, and cervical dysplasia.53 Support of this came from
experiments in both cell culture and murine xenografts, whereby
treatment of ACC with 9-cis RA resulted in decreased cell viability,
proliferation, and steroid hormone production.54,55 Our results offer
human genetic evidence for the importance of this therapeutically
relevant pathway in ACC onset and extends its relevance to
progression of both paediatric and adult ACC. It is intriguing to note
that a recent study of metastatic ACC tumours has identified an
enrichment of driver mutations in RA pathway genes, possibly
lending further support to the inactivation of this pathway being a
crucial step in ACC progression.56 In addition, alterations in the
retinoic acid pathway have also been linked recently to benign
adrenocortical tumours secreting aldosterone.57
In conclusion, our results offer human genetic evidence for the
importance of the druggable RA pathway in ACC onset and
extend its relevance to progression of both paediatric and adult
ACC. These findings will impact the design of future studies using
RA in pre-clinical studies and guide preventive actions following
genetic counselling and testing for children carriers of R337H
germline mutation.
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